# Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

> **NCT04165941** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 22 (actual)

## Conditions studied

- Brain Tumor Adult

## Interventions

- **BIOLOGICAL:** DRI cell therapy

## Key facts

- **NCT ID:** NCT04165941
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165941, "Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04165941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*